26B-4-243. Guidance for treatment with medical cannabis.
200 words·~1 min read·
/ut/title-26b/chapter-4/26b-4-243·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Effective 10/14/2025
26B-4-243. Guidance for treatment with medical cannabis.
The department, in consultation with the Center for Medical Cannabis Research created in Section 53H-4-206 , shall:
(1)develop evidence-based guidance for treatment with medical cannabis based on the latest medical research that shall include:
(a)for each qualifying condition, a summary of the latest medical research regarding the treatment of the qualifying condition with medical cannabis;
(b)risks, contraindications, side effects, and adverse reactions that are associated with medical cannabis use; and
(c)potential drug interactions between medical cannabis and medications that have been approved by the United States Food and Drug Administration;
(2)educate recommending medical providers, pharmacy medical providers, medical cannabis cardholders, and the public regarding:
(a)the evidence-based guidance for treatment with medical cannabis described in Subsection (1)(a) ;
(b)relevant warnings and safety information related to medical cannabis use; and
(c)other topics related to medical cannabis use as determined by the department; and
(3)develop patient product information inserts for medical cannabis products:
(a)in consultation with the cannabis processing facility that created the product; and
(b)that do not contain proprietary information about the product.
Amended by Chapter 9 , 2025 Special Session 1